Literature DB >> 19242108

Downregulation of Wip-1 phosphatase expression in MCF-7 breast cancer cells enhances doxorubicin-induced apoptosis through p53-mediated transcriptional activation of Bax.

Weihong Kong1, Xiaoshan Jiang, W Edward Mercer.   

Abstract

The human breast cancer cell line MCF-7 carries an amplified PPM1 D/Wip-1 gene and over expresses Wip-1 phosphatase protein. MCF-7 cells also harbor a wild type p53 gene. We established stable isogenic lines (MCF-Sp53 clones) which exhibit decreased levels of p53 protein. We show that although the PPM1 D gene is amplified in MCF-7 cells it is still expressed in a p53-dependent manner. Stable isogenic cell lines derived from MCF-7 cells (designated MCF-clones) were also established in which Wip-1 expression is significantly decreased by a plasmid-based PPM1D antisense RNA. Decreasing Wip-1 expression sensitized MCF-clones to doxorubicin-induced apoptosis. The enhanced apoptotic response was correlated with increased phosphorylation of N-terrninal p53-Ser15 and -Ser46 and increased expression of the pro-apoptotic Bax gene at both the mRNA and protein level. The enhanced apoptotic response was blocked by Bax-siRNA knock down suggesting that the increased response was a result of increased Bax protein expression. Moreover, reporter gene assays using the Waf-1 and Bax promoters to drive a luciferase gene revealed that luciferase activity driven by the Bax promoter was enhanced in MCF-clones while luciferase activity driven by the Waf-1 promoter was decreased relative to parental MCF-7 cells. The study reveals a novel molecular mechanism involving Wip-1 phosphatase, p53 phosphorylation and an enhanced apoptotic response mediated by transcriptional activation of the pro-apoptotic Bax gene.   W. Edward Mercer Ph.D., who made great contributions to this paper, passed away on Thursday, October 30, 2008, after a brief illness. This paper is in memorial to his honorable attitude toward science and education.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19242108     DOI: 10.4161/cbt.8.6.7742

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  18 in total

1.  Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents.

Authors:  Anastasia R Goloudina; Kan Tanoue; Arlette Hammann; Eric Fourmaux; Xavier Le Guezennec; Dmitry V Bulavin; Sharlyn J Mazur; Ettore Appella; Carmen Garrido; Oleg N Demidov
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

2.  Role of wild-type p53-induced phosphatase 1 in cancer.

Authors:  Zhi-Peng Wang; Ye Tian; Jun Lin
Journal:  Oncol Lett       Date:  2017-07-27       Impact factor: 2.967

3.  Deficient DNA damage signaling leads to chemoresistance to cisplatin in oral cancer.

Authors:  Ling Wang; Adam J Mosel; Gregory G Oakley; Aimin Peng
Journal:  Mol Cancer Ther       Date:  2012-09-12       Impact factor: 6.261

Review 4.  Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response.

Authors:  Rebecca B Riggins; Mary M Mazzotta; Omar Z Maniya; Robert Clarke
Journal:  Endocr Relat Cancer       Date:  2010-08-16       Impact factor: 5.678

Review 5.  Wip1 phosphatase in breast cancer.

Authors:  A Emelyanov; D V Bulavin
Journal:  Oncogene       Date:  2014-11-10       Impact factor: 9.867

6.  PPM1D in Solid and Hematologic Malignancies: Friend and Foe?

Authors:  Linda Zhang; Joanne I Hsu; Margaret A Goodell
Journal:  Mol Cancer Res       Date:  2022-09-02       Impact factor: 6.333

7.  Nuclear factor-kappaB (NF-kappaB) is a novel positive transcriptional regulator of the oncogenic Wip1 phosphatase.

Authors:  Julie M Lowe; Hyukjin Cha; Qian Yang; Albert J Fornace
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

Review 8.  Regulation of the Wip1 phosphatase and its effects on the stress response.

Authors:  Julie Lowe; Hyukjin Cha; Mi-Ok Lee; Sharlyn J Mazur; Ettore Appella; Albert J Fornace
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

9.  Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.

Authors:  Sona Pechackova; Kamila Burdova; Jan Benada; Petra Kleiblova; Gabriela Jenikova; Libor Macurek
Journal:  Oncotarget       Date:  2016-03-22

Review 10.  WIP1 phosphatase as pharmacological target in cancer therapy.

Authors:  Soňa Pecháčková; Kamila Burdová; Libor Macurek
Journal:  J Mol Med (Berl)       Date:  2017-04-24       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.